Device Trial Radar · NCT04142658
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
Last checked: Nov 20, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
863
Actual
Start
May 1, 2020
Primary completion
Dec 12, 2022
Study completion Dec 12, 2022
Sponsor
- Lead sponsor
- Artivion Inc.Public (AORT)
- Sponsor type
- Industry
- Collaborators
- Duke Clinical Research Institute
- First posted
- Oct 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Currently, warfarin is the only approved anticoagulation for patients with mechanical valves. The purpose of this study is to determine if participants with an On-X Prosthetic Heart Valve / On-X aortic valve can be maintained safely and effectively on apixaban. Both the On-X aortic valve and apixaban have been approved for use by the US Food and Drug Administration (FDA) but they have not been approved to be used together.
Conditions
- Aortic Valve Disease
- Aortic Valve Stenosis
- Aortic Valve Failure
Interventions
Apixaban 5 MGDrug
For patients that do NOT meet the following criteria * age ≥ 80 years * weight ≤ 60 kilograms * creatinine ≥ 1.5 mg/dL (133 micromol/L)
Apixaban 2.5 MGDrug
For patients that meet at least 2 of the following criteria * age ≥ 80 years * weight ≤ 60 kilograms * creatinine ≥ 1.5 mg/dL (133 micromol/L)
WarfarinDrug
Active Control Intervention
On-X Aortic Mechanical ValveDevice
Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of Valve Thrombosis and Valve-related ThromboembolismTime frame: through study closure, a median follow-up of 13.5 months
- Major BleedingTime frame: through study closure, a median follow-up of 13.5 months
Locations
62 sites in 1 country. Site status is shown where the registry gives one.
Tucson Heart Center
Tucson, Arizona
CHI St. Vincent Heart Institute
Little Rock, Arkansas
Loma Linda University Medical Center
Loma Linda, California
59 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.